Journal
Oncotarget
Publication Date
2016
Volume
7
Issue
21
Inclusive Pages
31534-31549
Document Type
Open Access Publication
DOI
10.18632/oncotarget.8925
Rights and Permissions
Su, Y., Tatzel, K., Wang, X., Belt, B., Binder, P., Kuroki, L., Powell, M., Mutch, D., Hawkins, W., and Spitzer, D. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane. 2016. Oncotarget 2016 Apr 22: 1-16. doi: 10.18632/oncotarget.8925. Copyright: © Su et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Citation
Su, Yang; Tatzel, Katharina; Wang, Xuejun; Belt, Brian; Binder, Pratibha; Kuroki, Lindsay; Powell, Matthew A.; Mutch, David G.; Hawkins, William G.; and Spitzer, Dirk, "Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane." Oncotarget. 7, 21. 31534-31549. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/4885
